Tasha Lee

Tasha Lee serves as a key procurement professional within the National Institute of Allergy and Infectious Diseases (NIAID), supporting the agency’s mission to accelerate biomedical research for infectious, immunologic, and allergic disease threats. She manages complex acquisition portfolios focused on research and development, laboratory services, and biosafety infrastructure critical to public health preparedness. Her work directly enables the procurement of high-containment research capabilities, diagnostic platforms, and medical countermeasures, ensuring timely access to cutting-edge scientific resources. Lee’s acquisitions are strategically aligned with NIAID’s priority areas, including pandemic response readiness and advanced laboratory modernization. Her primary contractor relationships center on Quality Biological, Inc., a leading provider of biological reference materials and biosafety-grade reagents, and Genomic Labs Ltd., a specialized provider of genomic sequencing and analytical services. These partnerships reflect a preference for established, technically proficient vendors with proven expertise in high-containment research environments and regulatory-compliant biological product supply. Lee consistently engages with contractors capable of delivering specialized, non-commercially available solutions that meet stringent biosafety and quality control standards required for federal biomedical research. Lee’s procurement portfolio exhibits no set-aside preferences, with 100% of awards issued under full and open competition. This reflects a strategic emphasis on technical capability and mission-critical performance over socioeconomic categorization, prioritizing the most qualified vendors regardless of size or certification status. While small business participation is not formally incentivized, her contracting approach remains compliant with all federal acquisition regulations and supports equitable access where competitive bids meet technical requirements. Her primary NAICS focus is 541714 (Research and Development in Biotechnology), accounting for 75% of her acquisitions, with 25% in 541380 (Testing Laboratories and Services). She procures advanced biotech R&D services, pathogen characterization tools, high-throughput screening systems, and accredited diagnostic testing services, demonstrating deep expertise in life sciences contracting and the regulatory frameworks governing biosafety level 3 and 4 research infrastructure.